Lilly Alimta Lung Cancer Use Supported By FDA Cmte.; Safety Profile Cited

The favorable toxicity profile of Lilly's oncologic Alimta outweighs uncertain survival benefits in the second-line treatment of non-small cell lung cancer, FDA's Oncologic Drugs Advisory Committee agreed July 27